Infections with different serotypes of dengue can lead to severe complications due to antibody-mediated enhancement. When a person is infected with one serotype, they develop antibodies that neutralize that specific strain but do not provide immunity against other serotypes. If they later contract a different serotype, these antibodies can bind to the new virus without neutralizing it, facilitating its entry into cells through Fc receptors. This process can trigger a severe immune response characterized by massive cytokine release, contributing to complications like disseminated intravascular coagulation (DIC). Reinfection with the same serotype typically does not lead to severe illness, as the immune response is already primed against that specific strain. The discussion also touches on the ongoing challenges in developing effective vaccines for dengue and similar viruses, such as HIV, where sub-neutralizing antibodies may influence immune responses.